Surprisingly, over 50% of patients with colorectal cancer exhibit abnormal Gs pathway activation, which includes downstream effectors of Gαs such as PKA and adenylyl cyclases, activating mutations or gene amplification of GNAS. This evidence concerns the gene GAST and colorectal cancer.